Roth MKM Initiates Coverage On Cardiol Therapeutics with Buy Rating, Announces Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
Roth MKM initiates coverage on Cardiol Therapeutics (NASDAQ:CRDL) with a Buy rating and sets a price target of $10.
June 26, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roth MKM has initiated coverage on Cardiol Therapeutics with a Buy rating and a price target of $10, indicating strong potential for growth.
The initiation of coverage with a Buy rating and a $10 price target by Roth MKM is a positive signal for investors, suggesting confidence in the company's growth prospects. This is likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100